InvestorsHub Logo
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: midastouch017 post# 403

Sunday, 10/18/2009 4:43:16 AM

Sunday, October 18, 2009 4:43:16 AM

Post# of 1367
MediWound's Debrase hit two co-primary endpoints in its phase III trial and the trial will be stopped after treating the first 175 patients. Debrase will be marked by Teva and can be approved in Europe late next year.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.